Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Echols

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Open Forum Infectious Diseases|May 29, 2020
The Burden of Bloodstream Infections due to <i>Stenotrophomonas Maltophilia</i> in the United States: A Large, Retrospective Database StudyBin Cai, Glenn Tillotson, Darrin Benjumea, et al.
Jac-Antimicrobial Resistance|July 5, 2021
<i>In vitro</i> activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from EuropeChristopher Longshaw, Davide Manissero, Masakatsu Tsuji, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 3, 2006
Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitisJohn Upchurch, Michael Rosemore, Robert Tosiello, et al.
Infectious Diseases and Therapy|February 20, 2022
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical StudiesDavid L Paterson, Masahiro Kinoshita, Takamichi Baba, et al.
Therapeutic Advances in Infectious Disease|December 6, 2021
Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigationSimon Portsmouth, Roger Echols, Kiichiro Toyoizumi, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 13, 2022
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP studyEric P Skaar, Roger Echols, Yuko Matsunaga, et al.
Journal of Clinical Pharmacology|October 14, 2021
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy SubjectsNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
BMC Infectious Diseases|April 17, 2015
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infectionsRichard Vickers, Neil Robinson, Emma Best, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2016
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal FunctionTakayuki Katsube, Toshihiro Wajima, Toru Ishibashi, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelMarguerite L Monogue, Masakatsu Tsuji, Yoshinori Yamano, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Open Forum Infectious Diseases|May 29, 2020
The Burden of Bloodstream Infections due to <i>Stenotrophomonas Maltophilia</i> in the United States: A Large, Retrospective Database StudyBin Cai, Glenn Tillotson, Darrin Benjumea, et al.
Jac-Antimicrobial Resistance|July 5, 2021
<i>In vitro</i> activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from EuropeChristopher Longshaw, Davide Manissero, Masakatsu Tsuji, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 3, 2006
Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitisJohn Upchurch, Michael Rosemore, Robert Tosiello, et al.
Infectious Diseases and Therapy|February 20, 2022
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical StudiesDavid L Paterson, Masahiro Kinoshita, Takamichi Baba, et al.
Therapeutic Advances in Infectious Disease|December 6, 2021
Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigationSimon Portsmouth, Roger Echols, Kiichiro Toyoizumi, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 13, 2022
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP studyEric P Skaar, Roger Echols, Yuko Matsunaga, et al.
Journal of Clinical Pharmacology|October 14, 2021
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy SubjectsNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
BMC Infectious Diseases|April 17, 2015
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infectionsRichard Vickers, Neil Robinson, Emma Best, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2016
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal FunctionTakayuki Katsube, Toshihiro Wajima, Toru Ishibashi, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelMarguerite L Monogue, Masakatsu Tsuji, Yoshinori Yamano, et al.
Pageof 6